查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1984156

癌症微生物組定序市場：按技術、工作流程、樣本類型、應用和最終用戶分類－2026-2032年全球市場預測

Cancer Microbiome Sequencing Market by Technology, Workflow, Sample Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，癌症微生物組定序市場價值將達到 8.9754 億美元，到 2026 年將成長至 9.924 億美元，到 2032 年將達到 18.46 億美元，年複合成長率為 10.85%。

主要市場統計數據
基準年 2025 8.9754億美元
預計年份：2026年 9.924億美元
預測年份：2032年 18.46億美元
複合年成長率 (%) 10.85%

本書清晰而實用地說明如何將微生物組定序整合到腫瘤學研究中，從而改變研究設計、生物標記發現和轉化途徑。

分子生物學和定序技術的融合發展，為腫瘤學研究開闢了新的前沿領域：闡明宿主相關微生物群落作為癌症生物學關鍵調控因子的作用。本執行摘要說明了癌症微生物組定序如何從最初的探索性研究發展成為轉化研究、增強臨床診斷和治療方法的重要策略支柱。透過將微生物譜分析與腫瘤基因組學和免疫表現型分析相結合，研究人員和產業領袖可以揭示有助於生物標記選擇、患者分層和新型治療標靶識別的機制關係。

近期技術、計算和臨床方面的變化如何重新思考癌症微生物組定序的可重複性、臨床意義和轉化實用化？

癌症微生物組定序領域正經歷多項變革，其驅動力包括技術的成熟、計算科學的進步以及不斷變化的臨床需求。定序平台不斷提升讀長、通量和糾錯能力，從而增強了分類解析度和功能推論的準確性。同時，強大的生物資訊流程和基於雲端的分析技術的興起降低了從大規模隊列中提取多體學相關性的門檻。這些進步使得研究人員能夠更快地從假設生成過渡到假設檢驗，同時嚴格控制污染和批次效應。

評估美國關稅政策的變化如何影響以序列主導的腫瘤項目的採購、供應鏈韌性和營運計劃。

政策和貿易環境會影響高性能定序試劑、耗材和設備的成本結構和供應鏈韌性。 2025年，美國關稅調整和海關政策影響了採購計畫以及從全球供應商採購定序平台和試劑的相對經濟效益。這些調整對實驗室規劃、資本投資和供應商選擇流程產生了連鎖反應，促使許多機構重新評估其供應商多元化策略和庫存管理實踐。

將定序技術、臨床應用、工作流程組件、最終使用者期望和樣本特定考慮因素與策略研究設計連結起來的綜合細分分析。

對細分市場的深入理解對於設計能夠協調技術、臨床需求和營運能力的研發和商業策略至關重要。本報告基於技術，探討了16S rRNA定序、鳥槍法宏基因組定序和全基因組定序的相對優點和限制。 16S rRNA定序在經濟高效的分類學研究中仍然非常有用；鳥槍法宏基因組定序能夠實現物種層級的解析度和功能基因檢驗；而全基因組定序則透過同時分析宿主和微生物基因組，提供全面的基因組背景資訊。這些差異會影響針對特定研究挑戰在定序深度、廣度和可解釋性方面的選擇。

美洲、歐洲、中東和非洲以及亞太地區的區域趨勢和基礎設施將決定轉化途徑和合作研究的機會。

區域趨勢正以不同的方式影響科學合作、監管預期和基礎設施建設。在美洲，隨著臨床實驗室網路和商業性診斷技術的擴展，定序基礎設施和轉化腫瘤學的投資日趨成熟，為整合微生物組和腫瘤學方法創造了沃土。集中式核心設施、臨床研究機構以及官民合作關係的便利，正在加速將微生物生物標記轉化為臨床實驗室方案和治療假設的進程。

深入了解平台創新者、試劑供應商、生物資訊公司和臨床檢查室如何合作與競爭，以提供檢驗的癌症微生物組定序解決方案。

圍繞癌症微生物組測序的競爭與合作生態系統涵蓋了平台供應商、試劑供應商、生物資訊公司、臨床檢查室和轉化研究團隊。定序平台供應商不斷在通量、準確性和易用性方面進行創新，而試劑和耗材製造商則專注於試劑盒標準化和污染控制。生物資訊學公司憑藉其專有演算法脫穎而出，這些演算法能夠提高分類解析度、功能註釋和臨床級報告的質量，而臨床檢查室則正在建立符合CLIA標準的流程，以支援符合監管要求的檢測。

為產業領導者提供切實可行的建議，以改善通訊協定、實現供應鏈多元化並整合分析能力，從而提供臨床可靠的微生物組衍生腫瘤學見解。

產業領導者可以將技術、工作流程和區域知識的整合轉化為具體的行動，從而加速產生影響。首先，應優先考慮檢驗的樣本製備通訊協定和污染控制措施，將其作為基礎性投資。如果沒有可重複的樣本處理，即使採用先進的下游分析技術，其轉換價值也十分有限。其次，透過採用平台無關的分析框架，並在互補的定序技術之間交叉檢驗關鍵見解，來減少供應商鎖定並提高穩健性。整合結合分類學分析、功能推理和統計學嚴謹性的生物資訊流程，以產生可供臨床醫生和監管機構評估的可解釋生物標記。

結合專家訪談、通訊協定審核和三角測量技術證據的穩健混合調查方法，為可靠的操作指導提供了基礎。

本報告的調查方法結合了質性研究和第二手資料的系統整合，以確保研究的深度和可靠性。一手資訊來源包括對實驗室負責人、生物資訊經理、臨床研究人員和監管顧問的結構化訪談，從而獲得關於營運挑戰和檢驗重點的第一手觀點。此外，還對定序平台和試劑系統進行了通訊協定審查和技術評估，以評估與腫瘤微生物組研究相關的性能特徵。

簡要總結了為什麼嚴格的通訊協定、可互通的分析和協作的證據生成對於實現癌症微生物組測序的轉化潛力至關重要。

總之，癌症微生物組定序正處於一個關鍵的轉折點，技術可行性、電腦科學的成熟度和臨床需求在此交匯，為轉化應用創造了切實的機會。要充分發揮這一潛力，必須嚴格關注樣本完整性、分析可比較性和生物資訊透明度。當這些要素協調一致時，微生物訊號與腫瘤訊息相結合，有望用於患者分層、治療反應預測以及闡明新的標靶機制。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：癌症微生物定序市場：依技術分類

  • 16S rRNA測序
  • 鳥槍法元基因組組定序
  • 全基因組定序

第9章 癌症微生物定序市場：依工作流程分類

  • 分析
    • Illumina定序
    • 牛津奈米孔序列
    • PacBio定序
  • 生物資訊學
    • 功能分析工具
    • 統計分析工具
    • 分類分析工具
  • 預處理

第10章：癌症微生物定序市場：依樣本類型分類

  • 血液樣本
  • 糞便樣本
  • 組織樣本

第11章 癌症微生物定序市場：依應用領域分類

  • 乳癌
  • 結腸癌
  • 肺癌

第12章 癌症微生物定序市場：依最終用戶分類

  • 醫院和診所
  • 製藥和生物技術公司
  • 研究機構

第13章 癌症微生物定序市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 癌症微生物定序市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 癌症微生物定序市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國癌症微生物定序市場

第17章：中國癌症微生物組定序市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • AstraZeneca PLC
  • Athos Therapeutics Inc.
  • BGI Genomics Co., Ltd.
  • Bio-Rad Laboratories, Inc.
  • Bristol-Myers Squibb
  • CosmosID
  • Creative Biolabs
  • Danaher Corporation
  • Eurofins Scientific SE
  • Evelo Biosciences
  • EzBiome
  • F. Hoffmann-La Roche AG
  • Ferring Pharmaceuticals
  • Illumina, Inc.
  • LC Sciences
  • Merck KGaA
  • Metagen Therapeutics
  • MV BioTherapeutics SA
  • Norgen BIoTek Corp.
  • Novogene Co, Ltd.
  • Oxford Nanopore Technologies Ltd.
  • Pacific Biosciences of California, Inc.
  • QIAGEN NV
  • Roche Holding AG
  • Thermo Fisher Scientific Inc.
  • Vedanta Biosciences.
  • Viome Life Sciences, Inc.
Product Code: MRR-5C6F41F5AF92

The Cancer Microbiome Sequencing Market was valued at USD 897.54 million in 2025 and is projected to grow to USD 992.40 million in 2026, with a CAGR of 10.85%, reaching USD 1,846.00 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 897.54 million
Estimated Year [2026] USD 992.40 million
Forecast Year [2032] USD 1,846.00 million
CAGR (%) 10.85%

A clear and actionable primer explaining why integrating microbiome sequencing into oncological research transforms study design, biomarker discovery, and translational pathways

Advances in molecular biology and sequencing technologies have converged to create a new frontier in oncology research: the interrogation of host-associated microbial communities as integral modulators of cancer biology. This executive summary frames why cancer microbiome sequencing has moved beyond exploratory curiosity to a strategic pillar for translational research, clinical trial enrichment, and therapeutic innovation. By situating microbial profiling alongside tumor genomics and immunophenotyping, investigators and industry leaders can uncover mechanistic links that inform biomarker selection, patient stratification, and novel therapeutic targets.

The following pages synthesize cross-cutting evidence and operational considerations for technology selection, workflow design, regulatory navigation, and commercial alignment. Emphasis is placed on reproducibility, analytical sensitivity, and interpretive frameworks that translate sequencing output into clinically relevant insight. Throughout, attention is paid to assay comparability, sample handling constraints, and the bioinformatics approaches needed to move from raw reads to actionable biological signals. The goal is to provide an accessible yet rigorous foundation for decision-makers who must balance scientific ambition with practical constraints, enabling clearer pathways from study inception to clinical utility.

How recent technological, computational, and clinical shifts are reshaping cancer microbiome sequencing toward reproducibility, clinical relevance, and translational readiness

The landscape of cancer microbiome sequencing is undergoing several transformative shifts driven by technological maturation, computational advances, and evolving clinical priorities. Sequencing platforms have increased read lengths, throughput, and error correction capacity, which together improve taxonomic resolution and functional inference. Concurrently, the rise of robust bioinformatics pipelines and cloud-enabled analytics has lowered barriers to extracting multi-omic correlations across large cohorts. These developments mean that researchers can move faster from hypothesis generation to hypothesis testing, while maintaining stringent controls for contamination and batch effects.

In parallel, clinical stakeholders are beginning to demand evidence that microbial signatures are repeatable across populations and predictive of meaningful outcomes such as therapy response or adverse events. This demand has pushed study designs toward longitudinal sampling, standardized pre-analytical protocols, and harmonized analytical endpoints so that findings are more readily reproducible and clinically interpretable. Regulatory conversations are also shifting: rather than debating whether microbiome data can inform oncology decision-making, attention is increasingly focused on defining the evidentiary standards and validation pathways required to embed microbial biomarkers within therapeutic development programs. Together, these shifts create an environment where rigorous, reproducible microbiome sequencing can materially influence clinical trial design and therapeutic strategy.

Assessment of how evolving tariff policies in the United States have reshaped procurement, supply chain resilience, and operational planning for sequencing-driven oncology programs

Policy and trade environments influence the cost structure and supply chain resilience for high-throughput sequencing reagents, consumables, and instruments. In 2025, tariff changes and customs policies in the United States have affected procurement timelines and the relative economics of sourcing sequencing platforms and reagents from global suppliers. These adjustments have had ripple effects across laboratory planning, capital procurement, and vendor selection processes, prompting many organizations to revisit supplier diversification strategies and inventory management practices.

Practically, laboratories and institutions have responded by strengthening multi-vendor purchasing frameworks, negotiating longer-term supply agreements, and increasing local inventory buffers for critical consumables. Some stakeholders have accelerated adoption of platform-agnostic workflows and validated interchangeable reagents so that studies can be maintained despite episodic import disruptions. Contract research organizations and academic core facilities have also begun to articulate contingency plans that prioritize key ongoing studies, preserving longitudinal continuity for patient cohorts. In sum, regulatory and tariff dynamics have underscored the importance of supply chain resilience and strategic procurement in sustaining uninterrupted sequencing operations and protecting data integrity across long-term oncology studies.

Comprehensive segmentation analysis linking sequencing technology, clinical application, workflow components, end-user expectations, and sample-specific considerations to strategic study design

A nuanced appreciation of segmentation is essential to design studies and commercial strategies that align technology, clinical need, and operational capacity. Based on Technology, the report examines comparative advantages and limitations of 16S rRNA sequencing, which remains valuable for cost-effective taxonomic surveys; shotgun metagenomic sequencing, which enables species-level resolution and functional gene detection; and whole genome sequencing, which offers comprehensive genomic context when host and microbial genomes are interrogated concurrently. These distinctions drive choices about depth, breadth, and interpretive scope for a given research question.

Based on Application, the work explores how different oncological contexts-Breast Cancer, Colorectal Cancer, and Lung Cancer-present unique opportunities and constraints for microbiome analysis. Tumor site, microenvironmental interactions, and clinical workflows influence sampling strategies and biomarker strategies, necessitating application-specific validation paths. Based on Workflow, emphasis is placed on the three interconnected stages of Pre Analytical, Analytical, and Bioinformatics. The Analytical domain is further evaluated across sequencing platforms including Illumina sequencing, Oxford Nanopore sequencing, and PacBio sequencing to elucidate trade-offs in read length, error profiles, and throughput. The Bioinformatics domain is further examined through the lens of Functional Analysis Tools that infer metabolic potential, Statistical Analysis Tools that support cohort-level inference, and Taxonomic Profiling Tools that recover community composition from sequencing data.

Based on End User, the analysis considers decision drivers for Hospitals And Clinics that require clinical-grade robustness, Pharmaceutical And Biotechnology Companies focused on biomarker qualification and companion diagnostic pathways, and Research Institutes that prioritize methodological innovation and mechanistic inquiry. Based on Sample Type, practical guidance is provided for blood samples that enable minimally invasive longitudinal monitoring, fecal samples that capture gut ecosystem dynamics, and tissue samples that preserve tumor microenvironment context. Integrating these segmentation lenses supports tailored study designs and commercialization approaches that account for technical constraints, regulatory expectations, and end-user needs.

Regional dynamics and infrastructure realities across the Americas, Europe, Middle East & Africa, and Asia-Pacific that determine translational pathways and collaborative opportunities

Regional dynamics shape scientific collaboration, regulatory expectations, and infrastructure preparedness in distinct ways. In the Americas, investments in sequencing infrastructure and translational oncology have matured alongside expanding networks of clinical trials and commercial diagnostic development, creating fertile ground for integrated microbiome-oncology initiatives. Access to centralized core facilities, clinical research organizations, and public-private partnerships accelerates the translation of microbial biomarkers into clinical test plans and therapeutic hypotheses.

In Europe, Middle East & Africa, the landscape is heterogeneous, with pockets of advanced genomic capacity in some countries and emerging capabilities in others. Regulatory harmonization efforts and pan-European consortia are enabling cross-border studies, but stakeholders must navigate variable reimbursement frameworks and ethical review processes. Capacity building and standardized protocols are key priorities to ensure that datasets from diverse geographies are comparable and clinically meaningful. In the Asia-Pacific region, rapid adoption of sequencing platforms, increasing clinical trial activity, and strong public sector investment in precision oncology are driving high-volume data generation. However, differences in sample logistics, data governance regimes, and local clinical practices necessitate careful operational planning to ensure cross-regional data interoperability and compliance with local regulations. Taken together, regional insights emphasize the need for adaptive study architectures that respect local constraints while enabling global evidence generation.

Insights into how platform innovators, reagent suppliers, bioinformatics firms, and clinical laboratories are collaborating and competing to deliver validated cancer microbiome sequencing solutions

The competitive and collaborative ecosystem around cancer microbiome sequencing includes platform manufacturers, reagent suppliers, bioinformatics companies, clinical laboratories, and translational research groups. Sequencing platform vendors have continued to innovate on throughput, accuracy, and ease of use, while reagent and consumable manufacturers focus on kit standardization and contamination control. Bioinformatics firms are differentiating through proprietary algorithms that enhance taxonomic resolution, functional annotation, and clinical-grade reporting, and clinical laboratories are building CLIA-equivalent workflows to support regulatory-compliant testing.

Strategic partnerships between instrument vendors and bioinformatics providers are enabling bundled solutions that reduce deployment friction for clinical and research customers. At the same time, collaborations among pharmaceutical companies, academic centers, and clinical networks are facilitating access to well-annotated cohorts for hypothesis-driven studies. New entrants are targeting niche opportunities such as targeted microbial gene panels or integrated host-microbiome pipelines for immune-oncology applications. For organizations planning alliances or vendor selections, the emphasis should be on compatibility with standardized protocols, demonstrated contamination control, and clear pathways for analytical validation and clinical interpretation. Ultimately, company strategies that prioritize interoperability and evidence generation will be better positioned to support reproducible, clinically relevant outcomes.

Actionable recommendations for industry leaders to strengthen protocols, diversify supply chains, and integrate analytics to deliver clinically credible microbiome-derived oncology insights

Industry leaders can translate the synthesis of technology, workflow, and regional insights into concrete actions that accelerate impact. First, prioritize validated pre-analytical protocols and contamination control measures as foundational investments; without reproducible sample handling, downstream analytical sophistication yields limited translational value. Next, adopt platform-agnostic analytical frameworks and cross-validate key findings across complementary sequencing technologies to reduce vendor lock-in and improve robustness. Integrate bioinformatics pipelines that combine taxonomic profiling with functional inference and statistical rigor to produce interpretable biomarkers that clinicians and regulators can evaluate.

Additionally, cultivate multi-stakeholder collaborations that pair clinical cohorts with laboratory capacity and advanced analytics, thereby shortening the path from discovery to clinical qualification. Strengthen supply chain resilience by diversifying vendors and negotiating contingency provisions for critical consumables. From an organizational perspective, invest in workforce development in both wet-lab best practices and computational genomics so that teams can manage end-to-end workflows. Finally, engage proactively with regulatory bodies and standards organizations to help shape practical validation pathways and clinical utility criteria that reflect the unique complexities of host-microbiome data.

A robust mixed-method research methodology combining expert interviews, protocol audits, and triangulated technical evidence to support reliable operational guidance

The research methodology underpinning this report blends primary qualitative engagement with systematic secondary synthesis to ensure both depth and credibility. Primary inputs include structured interviews with laboratory directors, bioinformatics leaders, clinical investigators, and regulatory advisors, providing first-hand perspectives on operational challenges and validation priorities. These interviews were complemented by protocol reviews and technical assessments of sequencing platforms and reagent systems to evaluate performance characteristics relevant to oncology-focused microbiome studies.

Secondary analysis incorporated peer-reviewed literature, regulatory guidance documents, and technical white papers to contextualize technological performance and clinical applications. Data triangulation was used to reconcile divergent viewpoints and to identify consensus best practices, with particular attention to pre-analytical variables, contamination controls, and bioinformatics reproducibility. Quality assurance processes included cross-validation of technical claims against independent protocol repositories and verification of analytical trade-offs through comparative platform assessments. Ethical and data governance considerations were examined to ensure recommendations respect patient privacy and jurisdictional compliance. Together, this mixed-method approach creates a transparent evidentiary basis for the report's operational and strategic guidance.

Concise synthesis highlighting why rigorous protocols, interoperable analytics, and collaborative evidence generation are essential to realize the translational promise of cancer microbiome sequencing

In conclusion, cancer microbiome sequencing stands at a pivotal moment where technical feasibility, computational maturity, and clinical need intersect to create tangible opportunities for translational impact. Achieving that potential requires disciplined attention to sample integrity, analytical comparability, and bioinformatics transparency. When these elements are aligned, microbial signals can complement tumor-centric information to inform patient stratification, predict therapeutic response, and reveal novel mechanistic targets.

Going forward, stakeholders should pursue harmonized protocols, invest in interoperable analytics, and foster collaborative networks that enable robust, reproducible studies across geographies and clinical contexts. With careful operational planning and a focus on evidence generation, the integration of microbiome sequencing into oncology programs can advance both scientific understanding and patient-centered outcomes, laying the groundwork for durable translational success.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cancer Microbiome Sequencing Market, by Technology

  • 8.1. 16S Rrna Sequencing
  • 8.2. Shotgun Metagenomic Sequencing
  • 8.3. Whole Genome Sequencing

9. Cancer Microbiome Sequencing Market, by Workflow

  • 9.1. Analytical
    • 9.1.1. Illumina Sequencing
    • 9.1.2. Oxford Nanopore Sequencing
    • 9.1.3. Pacbio Sequencing
  • 9.2. Bioinformatics
    • 9.2.1. Functional Analysis Tools
    • 9.2.2. Statistical Analysis Tools
    • 9.2.3. Taxonomic Profiling Tools
  • 9.3. Pre Analytical

10. Cancer Microbiome Sequencing Market, by Sample Type

  • 10.1. Blood Samples
  • 10.2. Fecal Samples
  • 10.3. Tissue Samples

11. Cancer Microbiome Sequencing Market, by Application

  • 11.1. Breast Cancer
  • 11.2. Colorectal Cancer
  • 11.3. Lung Cancer

12. Cancer Microbiome Sequencing Market, by End User

  • 12.1. Hospitals And Clinics
  • 12.2. Pharmaceutical And Biotechnology Companies
  • 12.3. Research Institutes

13. Cancer Microbiome Sequencing Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Cancer Microbiome Sequencing Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Cancer Microbiome Sequencing Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Cancer Microbiome Sequencing Market

17. China Cancer Microbiome Sequencing Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. Agilent Technologies, Inc.
  • 18.7. AstraZeneca PLC
  • 18.8. Athos Therapeutics Inc.
  • 18.9. BGI Genomics Co., Ltd.
  • 18.10. Bio-Rad Laboratories, Inc.
  • 18.11. Bristol-Myers Squibb
  • 18.12. CosmosID
  • 18.13. Creative Biolabs
  • 18.14. Danaher Corporation
  • 18.15. Eurofins Scientific SE
  • 18.16. Evelo Biosciences
  • 18.17. EzBiome
  • 18.18. F. Hoffmann-La Roche AG
  • 18.19. Ferring Pharmaceuticals
  • 18.20. Illumina, Inc.
  • 18.21. LC Sciences
  • 18.22. Merck KGaA
  • 18.23. Metagen Therapeutics
  • 18.24. MV BioTherapeutics SA
  • 18.25. Norgen Biotek Corp.
  • 18.26. Novogene Co, Ltd.
  • 18.27. Oxford Nanopore Technologies Ltd.
  • 18.28. Pacific Biosciences of California, Inc.
  • 18.29. QIAGEN N.V.
  • 18.30. Roche Holding AG
  • 18.31. Thermo Fisher Scientific Inc.
  • 18.32. Vedanta Biosciences.
  • 18.33. Viome Life Sciences, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CANCER MICROBIOME SEQUENCING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY WORKFLOW, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES CANCER MICROBIOME SEQUENCING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA CANCER MICROBIOME SEQUENCING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY 16S RRNA SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY 16S RRNA SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY 16S RRNA SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY SHOTGUN METAGENOMIC SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY SHOTGUN METAGENOMIC SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY SHOTGUN METAGENOMIC SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY ANALYTICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY ANALYTICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY ANALYTICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY ANALYTICAL, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY ILLUMINA SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY ILLUMINA SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY ILLUMINA SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY OXFORD NANOPORE SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY OXFORD NANOPORE SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY OXFORD NANOPORE SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PACBIO SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PACBIO SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PACBIO SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY BIOINFORMATICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY BIOINFORMATICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY BIOINFORMATICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY FUNCTIONAL ANALYSIS TOOLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY FUNCTIONAL ANALYSIS TOOLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY FUNCTIONAL ANALYSIS TOOLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY STATISTICAL ANALYSIS TOOLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY STATISTICAL ANALYSIS TOOLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY STATISTICAL ANALYSIS TOOLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TAXONOMIC PROFILING TOOLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TAXONOMIC PROFILING TOOLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TAXONOMIC PROFILING TOOLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRE ANALYTICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRE ANALYTICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PRE ANALYTICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY BLOOD SAMPLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY BLOOD SAMPLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY BLOOD SAMPLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY FECAL SAMPLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY FECAL SAMPLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY FECAL SAMPLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TISSUE SAMPLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TISSUE SAMPLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TISSUE SAMPLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS CANCER MICROBIOME SEQUENCING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS CANCER MICROBIOME SEQUENCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS CANCER MICROBIOME SEQUENCING MARKET SIZE, BY ANALYTICAL, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS CANCER MICROBIOME SEQUENCING MARKET SIZE, BY BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS CANCER MICROBIOME SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY ANALYTICAL, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY ANALYTICAL, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY ANALYTICAL, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE CANCER MICROBIOME SEQUENCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE CANCER MICROBIOME SEQUENCING MARKET SIZE, BY ANALYTICAL, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE CANCER MICROBIOME SEQUENCING MARKET SIZE, BY BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE CANCER MICROBIOME SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST CANCER MICROBIOME SEQUENCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST CANCER MICROBIOME SEQUENCING MARKET SIZE, BY ANALYTICAL, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST CANCER MICROBIOME SEQUENCING MARKET SIZE, BY BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST CANCER MICROBIOME SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY ANALYTICAL, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC CANCER MICROBIOME SEQUENCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC CANCER MICROBIOME SEQUENCING MARKET SIZE, BY ANALYTICAL, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC CANCER MICROBIOME SEQUENCING MARKET SIZE, BY BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC CANCER MICROBIOME SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 140. ASEAN CANCER MICROBIOME SEQUENCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN CANCER MICROBIOME SEQUENCING MARKET SIZE, BY ANALYTICAL, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN CANCER MICROBIOME SEQUENCING MARKET SIZE, BY BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN CANCER MICROBIOME SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. GCC CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GCC CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 148. GCC CANCER MICROBIOME SEQUENCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 149. GCC CANCER MICROBIOME SEQUENCING MARKET SIZE, BY ANALYTICAL, 2018-2032 (USD MILLION)
  • TABLE 150. GCC CANCER MICROBIOME SEQUENCING MARKET SIZE, BY BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 151. GCC CANCER MICROBIOME SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. GCC CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 153. GCC CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPEAN UNION CANCER MICROBIOME SEQUENCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION CANCER MICROBIOME SEQUENCING MARKET SIZE, BY ANALYTICAL, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION CANCER MICROBIOME SEQUENCING MARKET SIZE, BY BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION CANCER MICROBIOME SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 164. BRICS CANCER MICROBIOME SEQUENCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS CANCER MICROBIOME SEQUENCING MARKET SIZE, BY ANALYTICAL, 2018-2032 (USD MILLION)
  • TABLE 166. BRICS CANCER MICROBIOME SEQUENCING MARKET SIZE, BY BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 167. BRICS CANCER MICROBIOME SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. G7 CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. G7 CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 172. G7 CANCER MICROBIOME SEQUENCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 173. G7 CANCER MICROBIOME SEQUENCING MARKET SIZE, BY ANALYTICAL, 2018-2032 (USD MILLION)
  • TABLE 174. G7 CANCER MICROBIOME SEQUENCING MARKET SIZE, BY BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 175. G7 CANCER MICROBIOME SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. G7 CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 177. G7 CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. NATO CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. NATO CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 180. NATO CANCER MICROBIOME SEQUENCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 181. NATO CANCER MICROBIOME SEQUENCING MARKET SIZE, BY ANALYTICAL, 2018-2032 (USD MILLION)
  • TABLE 182. NATO CANCER MICROBIOME SEQUENCING MARKET SIZE, BY BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 183. NATO CANCER MICROBIOME SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. NATO CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 185. NATO CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL CANCER MICROBIOME SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES CANCER MICROBIOME SEQUENCING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED STATES CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 189. UNITED STATES CANCER MICROBIOME SEQUENCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 190. UNITED STATES CANCER MICROBIOME SEQUENCING MARKET SIZE, BY ANALYTICAL, 2018-2032 (USD MILLION)
  • TABLE 191. UNITED STATES CANCER MICROBIOME SEQUENCING MARKET SIZE, BY BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 192. UNITED STATES CANCER MICROBIOME SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED STATES CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED STATES CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. CHINA CANCER MICROBIOME SEQUENCING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 196. CHINA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 197. CHINA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY WORKFLOW, 2018-2032 (USD MILLION)
  • TABLE 198. CHINA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY ANALYTICAL, 2018-2032 (USD MILLION)
  • TABLE 199. CHINA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY BIOINFORMATICS, 2018-2032 (USD MILLION)
  • TABLE 200. CHINA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. CHINA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 202. CHINA CANCER MICROBIOME SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)